Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Another big drug firm is joining the mRNA therapy field. Pfizer is paying BioNTech $120 million to develop mRNA flu vaccines and offering up to $305 million more in potential milestone payments. Moderna Therapeutics has already tested its own mRNA flu vaccine in a Phase I study. mRNA vaccines have also found an audience with nonprofit groups interested in making vaccines more cheaply and quickly during future pandemics.
This article has been sent to the following recipient: